Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.
IPO Year:
Exchange: NASDAQ
Website: altimmune.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $1.00 | Sell | Goldman |
| 2/28/2025 | Mkt Perform | William Blair | |
| 1/8/2025 | $18.00 | Buy | Stifel |
| 11/12/2024 | $26.00 | Buy | UBS |
| 4/29/2024 | Buy → Neutral | Guggenheim | |
| 1/24/2024 | $13.00 | Neutral | Goldman |
| 3/22/2023 | $20.00 → $6.00 | Buy → Neutral | Goldman |
| 12/1/2022 | $20.00 | Buy | Goldman |
| 12/29/2021 | $30.00 | Buy | Jefferies |
| 6/30/2021 | $41.00 → $21.00 | Buy | B. Riley Securities |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
3 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
3 - Altimmune, Inc. (0001326190) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Goldman resumed coverage of Altimmune with a rating of Sell and set a new price target of $1.00
William Blair initiated coverage of Altimmune with a rating of Mkt Perform
Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00
UBS initiated coverage of Altimmune with a rating of Buy and set a new price target of $26.00
Guggenheim downgraded Altimmune from Buy to Neutral
Goldman initiated coverage of Altimmune with a rating of Neutral and set a new price target of $13.00
Goldman downgraded Altimmune from Buy to Neutral and set a new price target of $6.00 from $20.00 previously
Goldman initiated coverage of Altimmune with a rating of Buy and set a new price target of $20.00
Jefferies resumed coverage of Altimmune with a rating of Buy and set a new price target of $30.00
B. Riley Securities reiterated coverage of Altimmune with a rating of Buy and set a new price target of $21.00 from $41.00 previously
Fastest customizable press release news feed in the world
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder (AUD). Fast Track designation is intended to accelerate the development and review of new drugs that target serious conditions and address unmet medical needs. RECLAIM (NCT06987513)
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A
Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board's
GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor R
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first patient in the RESTORE Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol-Associated Liver Disease (ALD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist in development for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), ALD and obesity. RESTORE (NCT07009860) is a randomized, placebo-controlled trial enrolling ap
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2
GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH). Conference Call InformationThe Company will host a conference call and webcast at 8:30 am E.T. on June 26, 2025. The call will include remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at the H
GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Details for the oral prese
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)Tuesday, May 20, 2025Fireside Chat at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 4, 2025Fireside Chat at 9:55 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section
Live Leadership Updates
Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effective August 12, 2025. Mr. Durso succeeds Mitchel Sayare, Ph.D., who will continue to serve on the Board as an Independent Director. The leadership transition is part of the Board's
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled
GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing, divestitures, collaborations, option
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Will Brown as Chief Financial Officer and member of the company's Executive Committee, effective January 1, 2022. "We are thrilled to welcome Will, a highly accomplished biopharmaceutical executive with proven business development and financial acumen, to ObsEva's executive team," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "This is an exciting time for ObsEva on the heels of the
This live feed shows all institutional transactions in real time.
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
DEF 14A - Altimmune, Inc. (0001326190) (Filer)
10-Q - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)
10-Q - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
EFFECT - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
S-3 - Altimmune, Inc. (0001326190) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
Live finance-specific insights
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A
GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor R
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2
GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH). Conference Call InformationThe Company will host a conference call and webcast at 8:30 am E.T. on June 26, 2025. The call will include remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at the H
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide Webcast to be held today, May 13, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceuti
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Feb.
GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on
Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash, cash equivalents and short-term investments of $139.4 million on September 30, 2024 Webcast to be held today, November 12, 2024, at 8:30 a.m. ET GAITHERSBURG, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for
GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay wi